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Studies of the pathogenesis of dengue hemorrhagic fever (DHF), a potentially life-threatening disease, have revealed the
importance of initial high levels of virus replication. However, the possible involvement of virus during the transition from
fever to defervescence, a critical stage in determining the severity of disease, has not been appreciated. Using quantitative
reverse transcription-polymerase chain reaction, we examined the levels of plasma dengue viral load during both fever and
defervescence periods in patients from a DEN-3 outbreak in southern Taiwan in 1998. Higher levels of plasma dengue viral
RNA were found in DHF patients than in DF patients. During defervescence, while the level of plasma dengue viral RNA was
undetectable in most DF patients, it remains high in all DHF patients. Using a modified immunoprecipitation assay, we
demonstrated for the first time that the plasma dengue viruses persisting during defervescence were in the immune
complexes for most DHF patients. These findings suggest that continued active viral replication or delay in the clearance of
viremia contributes to the pathogenesis of DHF. Moreover, high levels of plasma dengue viral RNA during defervescence mayKey Words: dengue virus; pathogenesis; quantification; i
INTRODUCTION
Among the 70 or so arthropod-borne flaviviruses, out-
breaks of the four serotypes of dengue virus (DEN-1,
DEN-2, DEN-3, and DEN-4) continue to be a major public
health problem in tropical and subtropical areas
(Monath, 1994; Innis, 1995; Gubler, 1998). While most
dengue virus infections develop as asymptomatic or
mild, self-limited illness, in the form of dengue fever (DF),
some patients may develop severe and potentially life-
threatening diseases, dengue hemorrhagic fever–den-
gue shock syndrome (DHF/DSS) (Innis, 1995; WHO, 1997;
Gubler, 1998). It has been estimated that approximately
100,000,000 dengue infections occur annually throughout
the world (Halstead, 1988; Monath, 1994; Gubler, 1998).
The initial clinical presentations of DF and DHF/DSS
are similar, both including a sudden onset of fever and a
variety of nonspecific symptoms and signs (Innis, 1995;
WHO, 1997; Gubler, 1998). It is at the time of deferves-
cence that severe hemorrhage and circulatory failure
occur in DHF/DSS patients. Without early diagnosis and
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prompt treatment, patients will die quickly (Innis, 1995;
WHO, 1997; Gubler, 1998).
Along with other valuable insights, two major hypoth-
eses, the immune and the viral hypotheses, have been
proposed regarding the pathogenesis of DHF/DSS (In-
nis, 1995; Gubler, 1998). The immune hypothesis at-
tempts to explain the epidemiological observations that
individuals experiencing secondary infections with a het-
erologous dengue serotype had a significantly higher
risk of developing DHF/DSS (Halstead, 1988; Burke et al.,
1988; Thein et al., 1997). Dengue viruses have been
shown to replicate to higher titers in human monocytes
in the presence of cross-reactive nonneutralizing anti-
bodies in vitro (Halstead and O’Rourke, 1977; Brandt et
al., 1982). The antibody-dependent enhancement (ADE)
phenomenon is believed to augment viral replication in
vivo by increasing the numbers of dengue-infected anti-
gen-presenting cells. The increase results in profound
activation of preexisting cross-reactive cytotoxic T-lym-
phocytes and the release of cytokines and cellular me-
diators, thus leading to subsequent immunopathological
processes and DHF/DSS (Innis, 1995; Gubler, 1998;
Green et al., 1999; Rothman and Ennis, 1999). The viral
hypothesis proposes that the severity of the disease isserve as a disease marker for DHF. © 2003 Elsevier Science (U
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may have evolved to replicate faster and to higher levelsSA)mmune
with greater epidemic potential, thus causing more se-
vere diseases (Rosen, 1977; Gubler et al., 1978; Leit-
meyer et al., 1999).
As suggested by both hypotheses, the outcome of
disease severity correlates directly with the magnitude of
viral replication. Investigations of various clinical, viro-
logical, and immunological parameters during the
course of infection have revealed the contribution of
initial high levels of virus replication to DHF/DSS
(Vaughn et al., 1997, 2000; Murgue et al., 2000; Libraty et
al., 2002). However, the involvement of viruses in the later
process, particularly during the transition from fever to
defervescence that is a critical stage in determining the
severity of diseases, has not been examined thoroughly.
Previously, we established a convenient and sensitive
quantitative competitive-reverse transcription-polymer-
ase chain reaction (QC-RT-PCR) assay for quantification
of dengue viruses (Wang et al., 2000). In this study, we
investigated the levels of plasma dengue viral load dur-
ing both fever and defervescence periods in patients
from a DEN-3 outbreak in southern Taiwan in 1998. We
report here that DHF patients continue to have high
levels of plasma dengue viral RNA during defervescence
and demonstrate that plasma dengue viruses persisting




The basic demographic, clinical, and virological infor-
mation on the 20 DEN-3 patients, including 11 DF and 9
DHF, are summarized in Table 1. The male-to-female ratio
was 1. The ages of the participants ranged from 23 to 70
years. There were no statistical differences in gender,
age, duration of fever, or sampling time between the DF
and DHF groups (P  0.5, Fisher’s exact two-tailed test,
P  0.33, P  0.41, and P  0.82, Mann–Whitney test,
respectively).
Quantification of plasma dengue RNA by RT-PCR
We first employed a QC-RT-PCR assay, modified from
a previously established method (Wang et al., 2000), to
investigate the levels of plasma dengue viral RNA. Figure
1 illustrates the results of QC-RT-PCR of two patients, ID
22 and ID 24. For ID 22, addition of increasing amounts
of the competitor RNA, Ci40-RNA, to replicate reactions
containing identical amounts of target RNA resulted in a
gradual increase in the intensity of the 210-bp product
and a gradual decrease in the intensity of the 170-bp
product (Fig. 1B, left). The point where the ratio of Cor.
Int. 210 to Int. 170 equals 1 (molar equivalence) repre-
sents the amount of target RNA, which was determined
TABLE 1












DF ID2 60 F d1–d5 d4 S 600
DF ID4 36 M d1–d5 d4 P 3,710,000
DF ID5 54 M d1–d2 d2 S 1,900,000
DF ID6 51 F d1–d4 d4 P 3,440,000
DF ID8 36 F d1–d9 d7 P 43,380
DF ID9 49 F d1–d5 d4 S 4620
DF ID13 69 M d1–d3 d7 (4) S 600
DF ID14 61 F d1–d6 d7 (1) S 600
DF ID15 36 F d1–d3 d8 (5) P 600
DF ID16 26 M d1–d4 d5 (1) P 600
DF ID17 28 M d1–d6 d7 (1) P 3900
DHF-2 ID18 57 M d1–d3 d3 S 124,860
DHF-2 ID19 67 M d1–d6 d3 S 14,900,000
DHF-3 ID20 57 F d1–d7 d4 P 1,530,000
DHF-2 ID21 23 F d1–d5 d4 P 1,960,000
DHF-2 ID22 67 F d1–d5 d8 (3) S 594,000
DHF-2 ID23 27 M d1–d7 d8 (1) P 3,970,000
DHF-2 ID24 63 M d1–d4 d5 (1) S 1,310,000
DHF-2 ID25 38 F d1–d6 d8 (2) P 107,000
DHF-3 ID26 70 M d1–d4 d7 (3) S 46,700
a Disease includes dengue fever (DF) and different grades of dengue hemorrhagic fever (DHF) (WHO, 1997).
b ID, identification.
c Fever period is defined as from the first day of fever (d1) to the last day of fever.
d Sampling time d1 is the first day of fever. Numbers in parentheses indicate the day of defervescence, 1 being the first day of defervescence.
e Primary (P) or secondary (S) infection is determined by the IgM and IgG capture ELISA and the HI titer at convalescence.
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to be 998 copies, corresponding to 594,000 copies of
RNA per milliliter plasma. For ID 24, the amount of RNA
was determined to be 2206 copies per reaction, corre-
sponding to 1,310,000 copies of RNA per milliliter plasma
(Fig. 1C). Of note was that for reactions near the equiv-
alent points, there was a third band migrating slower
than the 170- and 210-bp products (Fig. 1B, lanes of 100
to 5000 copies competitors, and Fig. 1C, lanes of 500 to
10,000 copies competitors). The slower migration pattern
and the prominence of the bands seen only in reactions
near the equivalent points suggest that these bands are
heteroduplex complexes between the two differently
sized products. Such heteroduplexes would not affect
the accuracy of our quantification, since it was based on
the relative amount of the product of the target to that of
the competitor RNA, and both products will in principle
be similarly affected by the formation of the heteroduplex
complex (Piatak et al., 1993; Freeman et al., 1999; Wang
et al., 2000).
High levels of plasma dengue RNA persisting
in DHF patients
The levels of plasma dengue RNA of the 20 patients
thus determined range from less than 600 copies to
14,900,000 copies of RNA per milliliter plasma (Table 1).
There is no significant difference in the levels of plasma
dengue RNA with regards to age, gender, or primary
FIG. 1. Quantification of plasma dengue viral RNA by the QC-RT-PCR assay. (A) Schematic diagram of the competitor construct, Ci40/pCRII-TOPO,
which contains a 40-bp insertion in the C region. (B, C) The results of the QC-RT-PCR assay for two patients, ID22 (B) and ID24 (C). The ethidium
bromide stained gels are on the left with the copy numbers of competitor RNA (Ci40-RNA) shown on top, and the plots of quantitative fluorescence
data on the right. m, molecular weight marker. The expected product size of dengue RNA (170 bp) and Ci40-RNA (210 bp) are indicated.
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versus secondary antibody response (P  0.93, ANOVA,
P  0.39, and P  0.53, Mann–Whitney test, respec-
tively). Compared with those in the DF patients, the
levels of dengue RNA in the DHF patients were signifi-
cantly higher (Fig. 2A, P  0.025, Mann–Whitney test).
We next analyzed the samples collected during the fever
and defervescence periods separately. When only febrile
patients were compared, the levels of plasma dengue
RNA in the DHF group, ID18 to ID21 (geometric mean:
6.19 log copies/ml), were higher than those in the DF
group, ID2 to ID9 (geometric mean: 5.08 log copies/ml),
though this has not reached statistical significance (P 
0.48, Mann–Whitney test) (Fig. 2B). During deferves-
cence, all DF patients except one have dengue RNA
below the detection limit. In contrast, all DHF patients
retain high levels of dengue RNA (geometric mean: 5.64
log copies/ml) (Fig. 2C). The difference was highly sig-
nificant (P  0.008, Mann–Whitney test).
Analysis of sequential plasma samples
The differences in plasma dengue RNA observed be-
tween DF and DHF patients suggest that there are dif-
ferent patterns of viremia during the transition from fever
to defervescence. To investigate such possibility, we
examined sequential plasma samples from six patients,
three DHF and three DF. One of the DHF patients was ID
18, from whom the first sample was taken on day 3 and
the second on day 9. The other two DHF patients (ID30
and ID31, both DEN-2) and the three DF patients (ID 27
and ID 28, DEN-3; and ID29, DEN-4) were identified
between 1999 and 2001. The clinical course and plasma
dengue RNA level are shown in Fig. 3. For all three DF
patients, the levels of dengue RNA declined to the level
below detection when the fever subsided (Figs. 3A–3C).
In contrast, dengue RNA remains in plasma for up to 6
days after defervescence in DHF patients (Fig. 3D–3F).
These results, though based on a small sample size
examined, are in agreement with the cross-sectional
observations and indicate that DF and DHF patients
have different patterns of viremia during the course of
infection. Moreover, these findings suggest that high
levels of plasma dengue RNA persisting after deferves-
cence may serve as a marker for DHF.
Dengue viruses in the immune complexes
It has been reported that anti-dengue IgM antibody
developed within 5 days of onset and were detectable in
FIG. 2. The relationship between plasma viral load and disease severity. (A) The levels of plasma dengue viral RNA (in log scale) of 11 DF and 9
DHF patients. (B, C) Subset analysis of samples obtained during the fever (B) and the defervescence (C) periods. Horizontal lines indicate geometric
means. Dashed lines indicate the limit of detection of the assay, i.e., 600 copies/ml plasma.
FIG. 3. Changes in the plasma dengue viral load during the transition
from fever to defervescence. (A, B, C) DF patients, ID 27, 28, and 29. (D,
E, F) DHF patients, ID 18, 30, and 31. The levels of sequential plasma
dengue RNA (in log scale) plotted by the day, hatched bars indicating
the fever period. Dashed lines indicate the limit of detection, 600
copies/ml plasma.
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more than 90% of the patients from day 6 to day 10
(Gubler, 1998; Vaughn et al., 1999). In this study, all five
defervescence samples from DHF patients (ID22 to 26)
had detectable anti-dengue antibodies (Table 1 and data
not shown). To investigate whether the dengue viruses
persisting at defervescence in the DHF patients were
contained in the immune complexes, we employed a
modified immunoprecipitation assay. In the reconstitu-
tion experiment, equal amounts of a DEN-2 virus were
preincubated with or without anti-dengue mAb before
incubation with immobilized protein G. Dengue viral RNA
isolated from the unbound and the bound fractions were
subjected to quantitative RT-PCR. A band of the expected
size of 170 bp was detected in the bound fraction of the
reaction containing a DEN-2 specific anti-envelope mAb,
3H5, but not in those containing no antibody or contain-
ing 5D4, a DEN-3-specific anti-NS1 mAb (Fig. 4A). The
proportion of bound fraction by 3H5 was calculated to be
33.3%.
We next incubated with immobilized protein G the
plasma from five DHF patients (ID 22 to 26) at deferves-
cence as well as plasma from five DF patients and
examined the amounts of dengue RNA in the unbound
and the bound fractions. With the exception of ID 25,
considerable amounts of dengue RNA, corresponding to
7.2 to 42.5% of the total, were detected in the bound
fractions of the defervescence plasma of the other four
DHF patients (Fig. 4B). In contrast, no dengue RNA was
found in the bound fractions of the control DEN-3 H87
virus or that of the plasma from DF patients, who have
either detectable anti-dengue antibodies (ID4, 8, 9, and
17) or have not yet developed antidengue antibody (ID6)
(Fig. 4B and data not shown).
DISCUSSION
In this study, we used the quantitative RT-PCR method,
which is more sensitive and convenient than virus iso-
lation, to investigate the relationship between plasma
dengue viral load and disease severity during the course
of infection (Piatak et al., 1993; Freeman et al., 1999;
Murgue et al., 2000; Wang et al., 2000; Sudiro et al., 2001).
Consistent with the outcome predicted by both immune
and viral theories, higher levels of dengue RNA were
seen in DHF patients than in DF patients, when compar-
ing all acute plasma samples together (Fig. 2A) (Rosen,
1977; Halstead, 1988; Innis, 1995; Gubler, 1998; Thein et
al., 1997). Uniquely, we found that DHF patients, in con-
trast to DF patients, continue to have high levels of
plasma dengue viral RNA during defervescence, a criti-
cal stage in determining the severity of disease. More-
over, we demonstrated for the first time that the plasma
dengue viruses persisting during defervescence were in
the immune complexes for most DHF patients. These
findings illustrate the importance of both viral and host
factors during the transition from fever to defervescence
and would provide new insights into our understanding
of the pathogenesis of dengue (Innis, 1995; Gubler, 1998;
Thein et al., 1997).
Using the PanBio IgM and IgG capture ELISA and the
HI tests, 10 primary infections were found among the 20
patients in this study (Table 1). The possibility of Japa-
nese encephalitis virus (JEV) infection was excluded,
since all cases were negative for the JEV IgM-ELISA (Shu
et al., 2000). Moreover, dengue viral signals were de-
tected by the two-round RT-PCR assay and confirmed by
DNA sequencing in all cases (data not shown). The
observation of a high proportion of primary infection is in
agreement with a recent report of the same outbreak by
another medical center in Taiwan (Huang et al., 2001).
This is probably due to the absence of dengue outbreak
since 1943 in the central district of Tainan city, in which
most cases of this study were found (King et al., 2000). A
strong association of secondary infection with older age
(older than 55 years old) through stratification analysis
further supports this interpretation (Fisher’s exact test,
P  0.005). These findings suggest that the epidemiol-
ogy of dengue in Taiwan is different from that in South-
east Asia, where predominantly secondary infections
were reported by pediatric studies (Gubler et al., 1981;
Vaughn et al., 1997, 2000). With the small sample size
studied here, secondary infection was not found to be
associated with DHF (Table 1, 5 secondary infections of
9 DHF cases versus 5 secondary infections of 11 DF
cases, P  0.5, Fisher’s exact two-tailed test).
The most interesting observation of this study was that
while most DF patients had undetectable plasma den-
gue RNA during defervescence, all DHF patients contin-
ued to have high levels (Fig. 2C). This striking difference
could not be attributed to earlier sampling for the DHF
FIG. 4. Detection of dengue viruses in the immune complexes. (A)
RT-PCR products of the RNA derived from the bound (B) and unbound
(U) fractions of a DEN-2 virus (left), and of the standard RNA (C-RNA)
from 10 to 10,000 copies (right). Lanes: total, incubated neither with
antibody nor protein G; mock, no RNA added; no Ab, not preincubated
with antibody; 5D4, a DEN-3 specific anti-NS1 mAb; 3H5, a DEN-2
specific anti-envelope mAb; m, molecular size marker. (B) RT-PCR
products of RNA derived from the B and U fractions of dengue viruses
in plasma of DF and DHF patients, as well as in culture supernatants
of a DEN-3 virus, H87. m, molecular size marker.
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group than for the DF group, since there is no significant
difference in the sampling time after fever between the
two groups (Table 1, P  1.0, Mann–Whitney test). This
observation was further confirmed by analysis of se-
quential samples (Fig. 3). Previous studies reported that
the magnitude of viremia, as measured by virus isolation,
did not vary significantly with the severity of disease
(Gubler et al., 1979, 1981). Vaughn et al. reported recently
that plasma viremia cleared up more quickly and were
therefore lower in DHF patients than in DF patients at
defervescence (Vaughn et al., 2000). Patients in Vaughn’s
study were children (18 months to 14 years old), whereas
patients in our study were adults (23 to 70 years old).
Differences in host immune response and disease pre-
sentations between children and adults have been ob-
served in other viral infections, such as lymphocytic
choriomeningitis virus and human and simian immuno-
deficiency viruses (Oldstone, 1987; Falloon et al., 1989;
Baba et al., 1995). Whether age may account for the
different duration and pattern of dengue viremia with
regards to disease severity remains to be investigated.
In Vaughn’s study, viremia was determined through
virus isolation, which detects intact virions, whereas vire-
mia was determined by the levels of RNA in our study. It
is worth noting that virus isolation could potentially en-
counter interference from the presence of antibodies or
immune complexes in the plasma, particularly in the
cases of secondary infection (Ruangjirachuporon et al.,
1979; Scott et al., 1980; Gubler et al., 1981; Vaughn et al.,
1997). Since more than 90% of the DHF patients were
cases of secondary infection (Vaughn et al., 2000), large
amounts of antibodies and/or immune complexes near
defervescence may result in lower efficiency of virus
isolation and lower viremia. Consistent with this inter-
pretation were two recent studies showing that higher
viremia (as determined by RT-PCR methods) in DHF
patients than in DF patients persists up to deferves-
cence, though at a level close to the limit of detection
(Murgue et al., 2000; Libraty et al., 2002). Another study
using QC-RT-PCR methods revealed that while many
patients had plasma dengue RNA levels below detection
by defervescence, approximately one-third retained de-
tectable dengue RNA (Sudiro et al., 2001). It is likely that
most of this one-third are DHF patients.
Our findings that plasma dengue RNA persists during
defervescence in all DHF patients and that considerable
amounts of them are in the immune complexes would
have important implications to our understanding of the
pathogenesis of dengue. Since larger numbers of in-
fected cells in DHF than in DF patients, as evidenced by
the levels of viremia, are assumed to have occurred
during the fever period, it is possible that residual RNA
continues to be released after defervescence in DHF
patients but not in DF patients. Alternatively, active viral
replication continues in DHF patients during deferves-
cence. This was supported by the observations that
DEN-3 virus can be isolated at later time points of infec-
tion from DHF patients, including ID22 and ID25 at day 8
(data not shown). Third, a large amount of defective
viruses are produced and therefore not detected by virus
isolation. RT-PCR with another primer pair targeting the
NS5 region was used to test our samples and revealed
essentially the same finding, i.e., that dengue viral RNA
were present in plasma in all DHF patients, but not in DF
patients, during defervescence (data not shown). This
suggests that defective viruses containing large genomic
deletions are unlikely to account for the viruses seen in
the DHF patients.
Another possibility is that the clearance of plasma
dengue viruses during defervescence is not as effective
in DHF patients as in DF patients, thus leading to sub-
sequent immunopathological processes. In this regard,
we found that dengue viruses were in the immune com-
plexes from four of five DHF patients at defervescence,
but not in such from four DF patients, who had detectable
anti-dengue antibodies (Fig. 4B and data not shown).
This is consistent with a previous report that circulating
immune complexes were found in 80% of DHF patients,
especially at the subsidence of fever (Ruangjirachuporon
et al., 1979). Of note was that the dengue virus-containing
immune complex observed in our DHF patients could not
be attributed to secondary antibody response, since it
was seen in both primary and secondary infections (Fig.
4B and Table 1). Several immune activation markers and
cytokines have been reported to be associated with
DHF/DSS (Gubler, 1998; Green et al., 1999; Rothman and
Ennis, 1999). Quantitative differences in host immune
responses and the timing of type 1 cytokine responses
were recently shown to have differing influences on the
severity of disease manifestations during secondary
DEN-3 virus infections (Libraty et al., 2002). Therefore, to
address the roles of the immune complexes in the patho-
genesis of DHF/DSS or in the clearance of viremia would
require future studies of the dynamic changes of the
virus-containing immune complex, and plasma viral load,
monitored by both viral RNA detection and virus isola-
tion, together with other immunological parameters, in-
cluding antibody titers and T cell immune responses
during the course of infection.
In summary, our findings suggest that high levels of
plasma dengue RNA during defervescence serve as a
disease marker of DHF. Based on our analysis, plasma
dengue RNA levels higher than 104 copies per milliliter at
day 2 of defervescence are able to distinguish DHF from
DF patients (Fig. 2C). Nonetheless, due to the dynamic
nature of viremia in dengue infection, further analysis of
more cases at comparable and multiple time points dur-
ing the transition from fever to defervescence is required
to define a cutoff value as the marker or predictor for the
development of DHF.
335PLASMA DENGUE VIRAL LOAD DURING DEFERVESCENCE
MATERIALS AND METHODS
Study participants
The diagnoses of DF and DHF followed the WHO
clinical definition (WHO, 1997). Detection of dengue
genomic sequences in plasma by a previously described
two-round RT-PCR assay, which included RT-PCR and a
second round PCR, was the laboratory criteria of confir-
mation for all cases (Lanciotti et al., 1992; WHO, 1997).
Between November and mid-December 1998, during an
outbreak in southern Taiwan, there were 20 dengue
patients at three hospitals (Chi-Mei Foundation Medical
Center, Kuo General Hospital, and Sin-Lau Christian
Hospital) confirmed at our laboratory (King et al., 2000).
The day of onset of fever (oral temperature 38°C) is
defined as day 1 of illness (d1). Defervescence is the
period that oral temperature is below 38°C without fur-
ther elevation, and the first day of defervescence (1) is
thus defined. Acute blood samples were collected in
EDTA-containing tubes between day 2 and day 8 of
illness. Plasma was prepared within 6 h of collection and
stored at 80°C until use (Wang et al., 2000). The pa-
tients were closely observed during hospitalization and
monitored with routine laboratory tests. After careful re-
view of the charts by infectious disease physicians, the
severity of disease was assessed by the WHO grading
system (WHO, 1997; Murgue et al., 2000; Vaughn et al.,
2000). The serotype of the 20 dengue patients was de-
termined to be DEN-3 using the two-round RT-PCR as-
say, which can distinguish the four dengue serotypes by
the size of the products (Lanciotti et al., 1992).
To determine primary or secondary dengue virus in-
fection, two methods were used in testing the convales-
cent sera. One is the commercial IgM and IgG capture
ELISA (PanBio Dengue Duo, Brisbane, Australia), which
contained stabilized dengue antigens (DEN-1 to DEN-4)
in one plate and anti-human IgM or anti-human IgG in
another plate (Vaughn et al., 1999). The ratio of the
absorbance at 450 nm of the patients’ sera (1:100 dilu-
tion) to that of the reference sera provided (cutoff cali-
brators, CO) were determined, and a ratio 1 was de-
fined as positive. An IgM/CO  1 and IgG/CO  3 are
considered primary infection, and an IgG/CO  3 is
considered secondary infection as described previously
(Vaughn et al., 1999). The other method is the traditional
hemagglutination inhibition (HI) test, in which primary (HI
titer  1280) or secondary (HI titer  1280) infection was
classified according to the WHO definition (WHO, 1997).
Both methods showed consistent results. In addition, all
serum samples were tested with a previously described
JEV-NS1 IgM ELISA to exclude JEV infection (Shu et al.,
2000), and all were negative.
Sequential samples, collected from 1999 to 2001, taken
at two to three time points, from three DF patients and
two DHF patients at the Kaoshiung Veterans General
Hospital and the Yuan General Hospital in southern Tai-
wan are also included in the analysis.
Isolation of viral RNA from plasma
Dengue viral RNA was isolated from plasma using the
QIAamp viral RNA mini kit (Qiagen, Germany) as de-
scribed previously (Wang et al., 2000).
RT-PCR primers
The primer pair, d3C14A and d3C69B, was modified
from a previously described primer pair, which can de-
tect all four dengue serotypes but not other flaviviruses
(Wang et al., 2000). The sequence of d3C14A was 5-
AATATGCTGAAACGCGTGAGAAACCG-3 (genome posi-
tions 134 to 159 of the DEN-3 H87 strain) (Osatomi and
Sumiyoshi, 1990), and the sequence of d3C69B was
5-CCCATCTAGCCAAGACTCCTGCTGT-3 (positions 278
to 302 of the H87 strain). They were designed to amplify
a 170-bp product for dengue RNA or a 210-bp product for
competitor RNA in the capsid (C) region.
Generation of the constructs and RNA
C/pCRII-TOPO was a plasmid containing the entire C
region and the N-terminal six amino acids of the precur-
sor membrane (PrM) region of DEN-3 strain H-87 in the
vector pCRII-TOPO (Invitrogen, San Diego, CA). The RNA
of the C region, C-RNA, was generated by T7 in vitro
transcription (Promega, Madison, WI) of the linealized
C/pCRII-TOPO, purified, and quantified (Wang et al.,
2000). The competitor construct, Ci40/pCRII-TOPO, was
modified from C/pCRII-TOPO by digestion with the re-
striction enzyme, HincII, followed by filling both 3 re-
cessed ends and inserting a 40-bp adaptor (Fig. 1A). The
competitor RNA, Ci40-RNA, was generated from the lin-
ealized Ci40/pCRII-TOPO and quantified (Wang et al.,
2000).
Quantitative RT-PCR
To obtain adequate quantification, RNA eluates from
some plasma samples were diluted 10- to 10,000-fold.
For the QC-RT-PCR assay, equal amounts (6 l) of the
diluted RNA eluates were mixed with increasing copy
numbers of Ci40-RNA and were subjected to RT-PCR. For
the noncompetitive quantitative RT-PCR, equal amounts
(6 l) of the RNA eluates and increasing copy numbers of
the C-RNA were subjected to RT-PCR simultaneously
under the conditions described previously (Wang et al.,
2000). The RT-PCR products were electrophoresed
through 2% agarose gel, stained, and measured. RT-PCR
products with the predicted size of 170 bp were seen in
most samples, but not in reactions containing no RNA, or
RNA from healthy donors, or when the RT step was
omitted.
For QC-RT-PCR, the ratios of the corrected intensity of
336 WANG ET AL.
210 bp (by a factor of 210/170) to that of 170 bp (Cor. Int.
210/Int. 170) were plotted against the copy number of the
competitor RNA (both in log scale), with the regression
line and coefficient of determination, R 2, determined. The
copy numbers of dengue RNA per reaction thus deter-
mined were used to calculate the RNA copies per milli-
liter plasma. The sensitivity was 10 copies RNA per
reaction as reported previously (Wang et al., 2000), cor-
responding to 600 copies RNA per milliliter plasma. For
noncompetitive RT-PCR, the intensity of the 170-bp prod-
ucts was plotted against the copy number of C-RNA (both
in log scale) to generate a standard curve. The copy
numbers of RNA per milliliter plasma were determined.
Detection of dengue viruses in the immune
complexes
Two murine antidengue monoclonal antibodies
(mAbs), 3H5 (a DEN-2 specific anti-envelope mAb) and
5D4 (a DEN-3 specific anti-NS1 mAb), were derived from
hybridomas, 3H5-1 and 5D4-11, respectively (American
Type Culture Collection, Rockville, MD) (Gentry et al.,
1982; Henchal et al., 1982). In the reconstitution experi-
ment, equal amounts of DEN-2 New Guinea virus were
incubated with or without antibody, at 4°C for 4 h, fol-
lowed by incubation with immobilized protein G, which
can bind human IgM and IgG, at 4°C for 4 h (Pierce,
Rockford, IL). The unbound fractions were removed after
centrifugation for 1 min. The immune complexes were
washed six times with 0.5 ml binding buffer and subse-
quently eluted with the elution buffer to obtain the bound
fractions (Pierce). Of note was that the amounts of den-
gue RNA derived from the unbound plus the bound
fractions were comparable to the total dengue RNA at
initial input, indicating that negligible amounts were lost
during washing (Fig. 4A). For detection of dengue viruses
in the circulating immune complexes, aliquots of plasma
and of culture supernatants of a DEN-3 virus, H87, were
incubated with protein G at 4°C for 4 h, followed by
washing and elution. Dengue viral RNA, isolated from the
unbound and bound fractions, was subjected to noncom-
petitive quantitative RT-PCR. The proportion of bound
RNA was calculated by the ratio of bound/bound 
unbound.
Statistical analysis
A nonparametric statistical method, the Mann–Whit-
ney test in the software SPSS base 8.0 (SPSS Inc., Chi-
cago, IL), was employed to compare age, fever duration,
sampling time, and levels of viral RNA between groups.
Fisher’s exact test was used to compare the difference in
gender and primary versus secondary infection between
DF and DHF patients.
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